Phase 2
N=90
AGN-229666 for the Treatment of Allergic Conjunctivitis
Allergic Conjunctivitis
Bottom Line
View on ClinicalTrials.gov: NCT01754766 ↗Enrolled (actual)
90
Serious AEs
0.0%
Results posted
Feb 2014
Primary outcome: Primary: Ocular Itching Score at Day 1 — 0.500; 0.319; 1.867 Score on a scale
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- AGN-229666 (Drug); vehicle of AGN-229666 (Other)
- Age
- Adult, Older Adult · 20+ yrs
- Sex
- All
- Sponsor
- Allergan
- Primary completion
- Jan 2013
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Ocular Itching Score at Day 1 |
0.500; 0.319; 1.867 | — |
| SECONDARY Ocular Itching Score at Day 15 |
0.358; 0.214; 1.258 | — |
| SECONDARY Conjunctival Hyperemia Score |
1.387; 1.345; 1.633 | — |
Summary
This study will evaluate the safety and efficacy of AGN-229666 for the treatment of allergic conjunctivitis.
Eligibility Criteria
Inclusion Criteria
- Japanese patients living in Japan with a history of allergic conjunctivitis
- Willing to discontinue wearing contact lenses during the study period
Exclusion Criteria
- Use of nicotine products during the study period
- Presence of active eye infection (bacterial, viral, or fungal)
- History of an ocular herpetic infection
- Eye surgery intervention within 3 months and/or a history of refractive surgery within the past 6 months
Data sourced from ClinicalTrials.gov (NCT01754766). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.